Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. She went home on day 2. Three weeks after PCI, new atrial fibrillation was found (nothing else changed): a DOAC was started, ticagrelor was changed to clopidogrel and aspirin was stopped, and she has taken the DOAC and clopidogrel since. Today is her 12-month visit: she is stable and still in atrial fibrillation.
This page helps you decide: The contrast case: had she stayed in sinus rhythm, what would her long-term antiplatelet therapy be at 12 months — should she continue dual antiplatelet therapy beyond 12 months? (In atrial fibrillation, needing an anticoagulant, she is outside this trial.)
After this page you can
Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.
Had Mrs. K. stayed in sinus rhythm, the DAPT Study would not argue for continuing DAPT past 12 months: it tested clopidogrel or prasugrel, not her ticagrelor, she meets ARC-HBR, and the gain (about one MACCE event prevented for every 63 treated) came with about one extra bleed for every 111 and an unresolved mortality signal. She would step down to one antiplatelet drug. In atrial fibrillation on an anticoagulant the trial does not govern her care at all. On the one-pager it sits on page 2, in the “Beyond 12 months — longer, or which one?” box.